Lissa Berroa Garcia, MD
Hospice and Palliative Medicine · Rockville, MDNPI 1770901498
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $217 and has fallen 82.8% since, to $37 in 2025.
Across 21 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$67
- Heron Therapeutics, Inc.$65
- Lilly USA, LLC$62
- Daiichi Sankyo Inc.$60
- Incyte Corporation$37
- ADC Therapeutics America, Inc.$30
- plus $156 from 7 others
What the payments were for
- Food & beverage$478100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 3 | $67 |
| Heron Therapeutics, Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $62 |
| Daiichi Sankyo Inc. | 2 | $60 |
| Incyte Corporation | 2 | $37 |
| ADC Therapeutics America, Inc. | 1 | $30 |
| Johnson & Johnson | 1 | $28 |
| Sanofi | 1 | $27 |
| Seagen Inc. | 1 | $26 |
| Spectrum Pharmaceuticals Inc. | 1 | $23 |
| Exelixis Inc. | 1 | $21 |
| AstraZeneca | 1 | $17 |
| Merck | 1 | $14 |
How this compares
$478 in reported general payments places this provider in the 65th percentile of 35 hospice and palliative medicine providers in Maryland.
See all hospice and palliative medicine providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydromorphone Hcl | 30 | $2,612 |
| Duloxetine Hcl | 15 | $1,938 |
| Fentanyl | 11 | $963 |
| Morphine Sulfate ErMorphine Sulfate | 28 | $467 |
| Oxycodone Hcl | 22 | $341 |
| Gabapentin | 30 | $257 |
| Morphine Sulfate | 14 | $147 |
| Dexamethasone | 12 | $129 |
| Trazodone Hcl | 17 | $100 |
| Lorazepam | 14 | $61 |
| Baclofen | 14 | $39 |
| Alprazolam | 12 | $2 |
| Zolpidem Tartrate | 12 | $0 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Rockville
- Kathleen McCabeRockville$379
- Geoffrey ColemanRockville$23
- Carlo GopezElkton$9K
- Benjamin GoldsteinCumberland$2K
- Amy HolstegeGlen Burnie$1K
- Margaret KeithAnnapolis$1K
- Paul NewmanLargo$1K
- Lee-Anne WestBaltimore$798
- Ivan ZamaGreenbelt$699
- David PressLanham$688
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.